WRF
TVTX icon

Waddell & Reed Financial’s Travere Therapeutics TVTX Stock Holding History

Waddell & Reed Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-154,971
Closed -$2.99M – 635
2015
Q4 		$2.99M Sell
154,971
-41,329
-21% -$826K ﹤0.01% 552
2015
Q3 		$3.98M Buy
+196,300
New +$5.81M 0.01% 519

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Waddell & Reed Financial's TVTX Position: Q1 2016 in Review

Waddell & Reed Financial sold out of Travere Therapeutics (TVTX) in Q1 2016, closing a stake of 154,971 shares — an estimated $2.99M sold.

Waddell & Reed Financial first reported a position in TVTX in Q3 2015 and held it in 2 quarters. The position peaked at $3.98M in Q3 2015. 119 funds tracked by Wall St. Rank hold TVTX as of Q1 2016.

  • Waddell & Reed Financial reported no remaining Travere Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Waddell & Reed Financial sold 154,971 Travere Therapeutics shares in Q1 2016, an estimated $2.99M.
  • Waddell & Reed Financial first reported a position in Travere Therapeutics in Q3 2015 and held it in 2 quarters.
  • Waddell & Reed Financial's Travere Therapeutics position peaked at $3.98M in Q3 2015.
  • 119 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2016.

Based on Waddell & Reed Financial's 13F filing for Q1 2016, filed 13 May 2016.